Crossmark

Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMT

Crossref DOI link: https://doi.org/10.1038/s41409-023-02048-7

Published Online: 2023-08-05

Published Print: 2023-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Tilmont, Rémi https://orcid.org/0000-0003-1739-2162
Yakoub-Agha, Ibrahim

Eikema, Diderik-Jan

Zinger, Nienke

Haenel, Mathias

Schaap, Nicolaas

Arroyo, Concepcion Herrera https://orcid.org/0000-0003-0055-2270
Schuermans, Christine

Besemer, Britta

Engelhardt, Monika https://orcid.org/0000-0003-0405-1676
Kuball, Jürgen https://orcid.org/0000-0002-3914-7806
Michieli, Mariagrazia

Schub, Natalie

Wilson, Keith M. O.

Bourhis, Jean Henri

Mateos, Maria Victoria https://orcid.org/0000-0003-2390-1218
Rabin, Neil

Jost, Edgar

Kröger, Nicolaus https://orcid.org/0000-0001-5103-9966
Moraleda, José M https://orcid.org/0000-0001-9080-1466
Za, Tommaso

Hayden, Patrick J. https://orcid.org/0000-0003-1374-4503
Beksac, Meral https://orcid.org/0000-0003-1797-8657
Mclornan, Donal https://orcid.org/0000-0003-1224-091X
Schönland, Stefan https://orcid.org/0000-0002-4853-5579
Manier, Salomon https://orcid.org/0000-0001-7653-711X
License Information

Text and Data Mining valid from 2023-08-05

Version of Record valid from 2023-08-05
More Information

Article History

Received: 26 March 2023

Revised: 30 June 2023

Accepted: 17 July 2023

First Online: 5 August 2023

Competing interests

: The authors declare no competing interests.

Document is current

Any future updates will be listed below